Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

ConferenceBHV-1530Positive

AI Analysis

Summary

Biohaven's Phase 1 clinical data on BHV-1530, a novel FGFR3-directed antibody-drug conjugate, has been selected for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in 2026. The presentation will feature findings from the ongoing BHV1530-101 study.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Phase 1 findings from BHV1530-101 study selected for oral presentation at EORTC-NCI-AACR Symposium 2026

Importance:5/10

Sentiment:

0.30

oncologyADCFGFR3Phase 1conference presentationearly-stage

Related Companies

$ISCO $MOLN $DFPH

Read the original article

Published by PR Newswire Pharma on September 28, 2026 11:30 AM

Read Original